| Species |
Mouse |
| Protein Construction |
IL-20RA (Val33-Lys253)_x000D_
Accession # Q6PHB0 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
IL-20RA hFc Chimera, Mouse captured on CM5 Chip via Protein A can bind Human IL20, His Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
52.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IL-20RA was highly expressed in the tumor tissue of CRC and related to the advanced stage.IL-20RA was involved in regulating oncogenic and immune pathways and affecting the expression of genes related to cell proliferation and immune evasion in CRC.Super-enhancer inhibition by JQ-1 or iBET-151 suppressed the growth of tumor cells and inhibited the expression of IL-20RA. |
| Synonyms |
IL-20R-alpha; IL-20RA; CRF2-8; IL-20R1; ZcytoR7; FLJ40993 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
